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Angiogenesis and an inflammatory infiltrate are conspic-
uous components Kaposi's sarcoma (KS). We found that
this inflam-matory component may play a key role in ang-
iogenesis, indicating that targeting inflammation is
needed to completely block angiogenesis. Like many ang-
iogenic molecules, HIV tat is also endowed with the
capacity to recruit both endothelial cells and leukocytes.
Angiogenesis is a common and key target of chemo-pre-
ventive molecules, a concept we termed "Angiopreven-
tion". Various chemoprevention molecules, such as
flavonoids, antioxidants and retinoids, are able to repress
growth of KS xenografts in vivo. These compounds act in
the tumor micro-environment inhibiting the recruitment
and/or activation of endothelial cells and innate immune
cells, particularly granuolocytes and macrophages. N-
acetyl-cysteine, the green tea flavonoid epigallocatechin-
3-gallate (EGCG) and the chalchone Xantohumol (XN)
all prevent angiogenesis in Matrigel sponges in vivo and
inhibit the growth of Kaposi's sarcoma tumor cells (KS-
Imm) in nude mice. Functional genomics analyses on the
effects of these compounds in primary endothelial cells
(HUVEC) in culture through Affymetrix GeneChip arrays
identified overlapping sets of genes regulated by the anti-
oxidants that centered on suppression the IkB/NF-kB sig-
nalling pathway. The repression of the NF-kB pathway
demonstrates anti-inflammatory effects for the anti-oxi-
dant compounds that indirectly inhibit angiogenesis, as
exemplified by EGCG. Focusing on approaches that block
inflammation will greatly enhance the effectiveness of
anti-angiogenesis approaches in both therapy and preven-
tion of cancer.
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